Core Viewpoint - The supervisory board of Jiangsu Hualv Biological Technology Group Co., Ltd. has verified the conditions and list for the second vesting period of the 2023 restricted stock incentive plan, confirming compliance with relevant laws and regulations [1][2]. Group 1 - The supervisory board ensures that the information disclosed is true, accurate, and complete, with no false records or misleading statements [1]. - The verification process was conducted in accordance with the Company Law, Securities Law, and the Management Measures for Incentive Plans, among other regulations [1]. - The supervisory board has approved the vesting of restricted stock for 35 eligible incentive objects, totaling 1,247,200 shares [2].

Core Viewpoint - Jiangsu Hualv Biological Technology Group Co., Ltd. announced the cancellation of 180,000 shares of unvested restricted stock from its 2023 incentive plan, which will not materially affect the company's financial status or operational results [1][3][4]. Summary by Sections Incentive Plan Approval Process - The company conducted necessary approvals for the 2023 restricted stock incentive plan, which included independent directors' agreement and the authorization from the second extraordinary general meeting of shareholders in 2023 [1][2]. Details of Canceled Restricted Stock - A total of 180,000 shares of restricted stock that were granted but not yet vested will be canceled as per the regulations outlined in the incentive plan and relevant management guidelines [3][4]. Impact of Canceled Restricted Stock - The cancellation of these shares will not have a substantial impact on the company's financial condition or operational performance, nor will it affect the stability of the management team or the ongoing implementation of the stock incentive plan [4]. Supervisory Board Opinion - The supervisory board concluded that the cancellation process complied with legal and regulatory requirements and did not harm the interests of the company or its shareholders, particularly minority shareholders [4]. Legal Opinion Conclusion - The legal opinion from Shanghai Jintiancheng Law Firm confirmed that the company has obtained necessary approvals and followed appropriate procedures regarding the adjustments and cancellations related to the incentive plan [4][5].

Core Viewpoint - The legal opinion letter from Shanghai Jintiancheng Law Firm confirms that Jiangsu Hualv Biotechnology Group Co., Ltd. has fulfilled the necessary conditions for the second vesting period of its 2023 restricted stock incentive plan and addresses the cancellation of certain unvested restricted stocks [3][4][19]. Group 1: Approval and Authorization - The company has obtained the necessary approvals and authorizations for the implementation of the vesting and cancellation of restricted stocks, including relevant resolutions from the board of directors and supervisory board [7][12][19]. - The independent directors have expressed their agreement with the incentive plan and related resolutions [8][12]. Group 2: Vesting Conditions and Achievements - The second vesting period for the restricted stocks is defined as starting from the first grant date and lasting until the last trading day within 36 months [12][13]. - The vesting conditions include the absence of adverse audit opinions and compliance with performance targets, which have been met as of the date of the legal opinion [13][15]. Group 3: Cancellation of Restricted Stocks - Due to the departure of six incentive targets, a total of 180,000 shares of unvested restricted stocks will be canceled [17][18]. - The cancellation has been approved by the board of directors and does not require further shareholder approval [18][19]. Group 4: Information Disclosure - The company will disclose relevant resolutions and announcements regarding the vesting and cancellation of restricted stocks in accordance with applicable laws and regulations [19].

Group 1 - The company Hualu Bio announced the approval of several proposals during the 12th meeting of the fifth supervisory board, including the achievement of the second vesting condition for the first grant of the 2023 restricted stock incentive plan [2]

Core Viewpoint - The company, Hualu Biological, announced the approval of several resolutions during the 14th meeting of its fifth board of directors, including the achievement of conditions for the second vesting period of the 2023 restricted stock incentive plan [2] Group 1 - The board meeting approved the proposal regarding the achievement of conditions for the second vesting period of the restricted stock incentive plan [2]

Core Viewpoint - Huagu Green Bio reported a revenue of 499 million yuan for the first half of 2025, reflecting a year-on-year growth of 7.78%, but the net profit attributable to shareholders was -53.69 million yuan, a decline of 19.79% compared to the previous year [1] Financial Performance - The basic earnings per share for the reporting period was -0.45 yuan, with a weighted average return on equity of -3.66% [2] - The company's gross margin for the first half of 2025 was -3.38%, down 3.75 percentage points year-on-year, while the net margin was -11.43%, a decrease of 1.63 percentage points from the same period last year [2] - In Q2 2025, the gross margin further declined to -16.18%, a year-on-year drop of 6.89 percentage points and a quarter-on-quarter drop of 23.58 percentage points; the net margin was -25.86%, down 2.64 percentage points year-on-year and down 26.58 percentage points quarter-on-quarter [2] Cost Structure - Total operating expenses for the first half of 2025 were 44.34 million yuan, a decrease of 3.13 million yuan compared to the previous year, with an expense ratio of 8.89%, down 1.37 percentage points year-on-year [2] - Sales expenses decreased by 15.35%, management expenses decreased by 13.61%, and R&D expenses decreased by 8.38%, while financial expenses increased significantly by 637.41% [2] Shareholder Information - As of the end of the first half of 2025, the total number of shareholders was 11,400, an increase of 1,171 households or 11.49% from the end of the previous quarter; the average market value held per household rose from 137,300 yuan to 153,400 yuan, an increase of 11.73% [3] Company Overview - Jiangsu Huagu Green Bio Technology Group Co., Ltd. was established on June 8, 2010, and listed on April 12, 2021; its main business involves the R&D, industrial cultivation, and sales of edible mushrooms [3] - The revenue composition of the main business includes enoki mushrooms (69.15%), king oyster mushrooms (25.44%), maitake mushrooms (2.65%), and others [3] - The company belongs to the agricultural, forestry, animal husbandry, and fishery industry, specifically in the planting sector focused on edible mushrooms [3]

江苏华绿生物科技集团股份有限公司2025年半年度非经营性资金占用及其他关联方资金往来情况汇总表 | 编制单位：江苏华绿生物科技集团股份有限公司 | | | | | | | | 单位：万元 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市 公司的关联关 | 上市公司核 算的会计科 | 2025年期初 占用资金余 | 2025年半年度占 用累计发生金额 | 2025年半年 度占用资金的 | 2025年半年 度偿还累计 | 2025年半年 度期末占用 | 占用形成原因 | 占用性质 | | | | 系 | 目 | 额 | （不含利息） | 利息(如有) | 发生金额 | 资金余额 | | | | 现大股东及其附属企业 | | | | | | | | | | | | 合计 | | | | | | | | | | | | 前大股东及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 总计 | | | | ...

Core Insights - The company reported a revenue of 499 million yuan for the first half of 2025, reflecting a year-on-year growth of 7.78% [1] - The net profit attributable to shareholders was a loss of 53.6947 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of 54.2082 million yuan [1] - The basic earnings per share were reported at -0.4467 yuan [1]

证券代码：300970 证券简称：华绿生物 公告编号：2025-026 江苏华绿生物科技集团股份有限公司 第五届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、监事会召开情况 江苏华绿生物科技集团股份有限公司（以下简称"公司"）第五届监事会第 十二次会议于 2025 年 8 月 26 日以现场和通讯相结合的方式在公司二楼会议室召 开，会议通知于 2025 年 8 月 20 日以通讯方式向全体监事送达。会议应出席监事 3 人，实际出席监事 3 人。公司董事会秘书列席了本次会议，会议由监事会主席 李贺文先生主持。本次监事会的召开符合《中华人民共和国公司法》等有关法律、 行政法规等规范性文件及《公司章程》的规定。 二、监事会审议情况 经与会监事认真审议，形成如下决议： 经审议，监事会认为： （一）审议通过了《关于<2025 年半年度报告>及其摘要的议案》 经审核公司《2025 年半年度报告》及其摘要，公司监事会认为： 董事会编制和审核公司 2025 年半年度报告及摘要的程序符合法律、行政法 规和中国证监会的规定，报告内容真实、准确、 ...

证券代码：300970 证券简称：华绿生物 公告编号：2025-025 一、董事会召开情况 江苏华绿生物科技集团股份有限公司（以下简称"公司"）第五届董事会第 十四次会议于 2025 年 8 月 26 日以现场和通讯相结合的方式在公司二楼会议室召 开，会议通知于 2025 年 8 月 20 日以通讯方式向全体董事发出。会议由董事长余 养朝先生召集并主持，会议应出席董事 9 人，实际出席董事 9 人，公司监事、高 级管理人员列席了本次会议。本次董事会的召开符合《中华人民共和国公司法》 等有关法律、行政法规等规范性文件及《公司章程》的规定。 二、董事会审议情况 经与会董事认真审议，形成如下决议： （一）审议通过了《关于<2025 年半年度报告>及其摘要的议案》 根据《公开发行证券的公司信息披露内容与格式准则第 3 号—半年度报告的 内容与格式》《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办 理》等监管要求，并结合公司的实际情况，公司编制了《2025 年半年度报告》 及《2025 年半年度报告摘要》。 江苏华绿生物科技集团股份有限公司 第五届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息 ...